Bafetinib
A potent and selective dual Abl/Lyn tyrosine kinase inhibitor with IC50 of 5.9 nM and 198 nM, respectively; more potent and specific against Bcr-Abl than imatinib, also inhibits the phosphorylation of CrkL and ERK in BaF3/E255K cells; inhibits the phosphorylation of Bcr-Abl harboring the M244V, G250E, Q252H, Y253F, E255K, E255V, F317L, M351T, E355G, F359V, H396P, or F486S mutations, but does not inhibit the phosphorylation of the T315I mutant; prolonges the survival of mice injected with leukemic cells expressing all mutated Bcr-Abl.Blood Cancer Phase 2 Clinical.
Product Specifications
CAS Number
859212-16-1
Product Name Alternative
INNO-406 | NS-187
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 42 mg/mL
Smiles
O=C (NC1=CC=C (C) C (NC2=NC=CC (C3=CN=CN=C3) =N2) =C1) C4=CC=C (CN5C[C@@H] (N (C) C) CC5) C (C (F) (F) F) =C4
Molecular Formula
C30H31F3N8O
Molecular Weight
576.6154
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Benzamide, N-[3- ([4,5'-bipyrimidin]-2-ylamino) -4-methylphenyl]-4-[[ (3S) -3- (dimethylamino) -1-pyrrolidinyl]methyl]-3- (trifluoromethyl) -
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Escherichia coli O157:H7 Molybdenum cofactor biosynthesis protein C (moaC)
Recombinant Escherichia coli O157:H7 Molybdenum cofactor biosynthesis protein C (moaC)
Recombinant Escherichia coli O157:H7 Molybdenum cofactor biosynthesis protein C (moaC)
Recombinant Escherichia coli O157:H7 Molybdenum cofactor biosynthesis protein C (moaC)
Recombinant Escherichia coli O157:H7 Molybdenum cofactor biosynthesis protein C (moaC)